Pyxis Oncology develops site-specific conjugated antibody-drug conjugates and immuno-oncology antibodies targeting the tumor microenvironment and immune checkpoints to treat difficult-to-treat solid tumors and hematologic malignancies.

Founded 2018

Massachusetts, United States

51-100

Publicly Traded
pyxisoncology.com

Highlights

Focus Areas

• Biotechnology
• Health Care
• Oncology
• Pharmaceutical

Recent Investors

• A
  R
  A
  R
  H
  J
  A
  L

Financials

• $174M Total Raised
• 2 Funding rounds
• 21 Investors

Team

Sign up to view the team

See the team members at Pyxis Oncology.